ANI Pharmaceuticals (ANIP) closed the last trading session at $58.64, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $77 indicates a 31.3% upside potential. The mean estimate comprises five short-term price targets with a standard deviation of $12.39. While the lowest estimate of $62 indicates a 5.7% increase from the current price level, the most optimistic analyst e ...

ANI Pharmaceuticals (ANIP) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inve ...

Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance • Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-year • Net loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 million • Diluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1 ...

Financial Performance and Key Metrics - The company reported total revenues of $148.3 million for Q3 2024, an increase of 13% compared to Q3 2023, driven by strong demand for Cortrophin Gel and growth in generics [12][28] - Adjusted non-GAAP EBITDA was $35.1 million, while adjusted non-GAAP EPS was $1.34, compared to $1.27 in the prior year [36] - Cortrophin Gel generated $52.6 million in revenues, up 77% year-over-year, with the highest number of new patient starts and unique prescribers since its launch [13][28] Business Line Performance - The generics business achieved revenues of $78.2 million, an increase of 11% over the prior year, reflecting strength in the base business and contributions from new product launches [14][31] - Revenues from established brands and other segments were $13.7 million, a decrease of 57% year-over-year, aligning with expectations [31] Market Data and Key Metrics - The overall ACTH category is expected to deliver more than 20% year-over-year growth in 2024, with Cortrophin Gel on a strong multi-year growth trajectory [14][50] - The company expects to capture $10 million in synergies from the Alimera acquisition by 2025, contributing to adjusted non-GAAP EBITDA of $35 million to $38 million [11][39] Company Strategy and Industry Competition - The acquisition of Alimera is seen as transformative for the Rare Disease business, with expectations of substantial shareholder value creation [11][39] - The company is focused on integrating the Alimera products and leveraging its expanded sales force to drive growth in ophthalmology and other specialties [9][27] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Cortrophin Gel and the overall Rare Disease segment, anticipating it to be the largest business unit and growth driver in 2025 [27][66] - The company raised its full-year 2024 guidance, reflecting continued strength in Cortrophin Gel and contributions from ILUVIEN and YUTIQ [39][40] Other Important Information - The company ended the quarter with $145 million in unrestricted cash and $641.3 million in outstanding debt, with gross leverage at approximately 3.8 times [37] - Non-GAAP gross margin was reported at 60%, a decrease of approximately 3.9 points from the prior year, primarily due to an unfavorable product mix [33] Q&A Session Summary Question: Can you talk about the payer landscape for Cortrophin Gel? - Management noted that the payer landscape is evolving, with increased affordability for seniors expected to improve patient access [48] Question: What is the mix of growth from existing versus new prescribers for Cortrophin? - Growth has come from both existing prescribers moving away from competitors and new prescribers unique to Cortrophin Gel [49][50] Question: What does the cadence of new launches for generics look like for 2025? - The company expects to continue a strong cadence of new launches, projecting growth in the high-single-digits to low double-digits for the generics business [51] Question: What is the expected quarterly run rate for ILUVIEN and YUTIQ going into next year? - Management indicated that the Q4 guidance reflects a transition period, with expectations for growth in 2025 [56] Question: How is the combined sales team impacting Cortrophin in ophthalmology? - Early signs are positive, and management remains confident in growth from the combined sales force [62] Question: What lessons were learned from the Alimera acquisition? - The company emphasized the importance of strategic alignment and addressing challenges effectively during acquisitions [68][70]

ANI Pharmaceuticals (ANIP) reported $148.33 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.5%. EPS of $1.34 for the same period compares to $1.27 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $143.97 million, representing a surprise of +3.03%. The company delivered an EPS surprise of +22.94%, with the consensus EPS estimate being $1.09.While investors closely watch year-over-year changes in headline numbers -- revenue and e ...

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 22.94%. A quarter ago, it was expected that this drugmaker would post earnings of $0.93 per share when it actually produced earnings of $1.02, delivering a surprise of 9.68%. Over the last four quarters, the c ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------|---------------------|------------------------------------------------------| | Title of each class: | Trading Symbol(s) | Name of each exchang ...

Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-yearNet loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 millionDiluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® with signific ...

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows: • The Guggenheim Inaugural Healthcare Innovation Conference Wednesday, November 13, 2024, at 10:00am ET • The Jefferies London Healthcare Conference Wednesday, November 20, 2024, at 2:30pm GMT/9:30am ET The liv ...

Wall Street expects a year-over-year decline in earnings on higher revenues when ANI Pharmaceuticals (ANIP) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 8, 2024, might help the stock move higher if these key numbers are bett ...